Patent classifications
C07D267/22
Azocane and azonane derivatives and methods of treating hepatitis B infections
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
Azocane and azonane derivatives and methods of treating hepatitis B infections
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:
##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:
##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:
##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:
##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.